Zogenix stock: buy or sell?

ZGNX stock price: $41.43 0.17% At close on September 20th, 2019

Updated on:
September 20th, 2019

0

Zogenix ended today at $41.43 and stayed stable a tight 0.17%. On Sep/11 ZGNX rocketed a dazzling 5.11%.

Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States.

Should I buy Zogenix stock?

Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. Having a trading plan helps to make decisions easier, quicker and with less hesitations. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.

None of our preferred buy setups matches with Zogenix stock situation right now, therefore this is not a suitable entry point.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This doesn't mean ZGNX will slide in coming sessions, or it will not rise higher. Simply, it doesn't match our recommended trading systems.

Is Zogenix stock a buy?

Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness. At Stocks2.com, we detected 15 ratings published for ZGNX stock in the last month.

The general sentiment of these ratings is bullish for ZGNX stock, with 12 positive ratings.
Is ZGNX a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-7-8Northland Securitiesn/aBuy
2019-6-28MizuhoBuyPositive
2019-6-28MizuhoBuyPositive
2019-6-27GuggenheimNeutralBuy
2019-4-9William Blairn/aBuy
2019-4-9Svb LeerinkOutperformOutperform
2019-4-9Stifel NicolausBuyBuy
2019-4-9Piper Jaffray CompaniesOverweightOverweight
2019-4-9Mizuhon/aBuy
2019-4-9Leerink Swannn/aOutperform
2019-4-9GuggenheimBuyNeutral
2019-4-5Northland Securitiesn/aBuy
2019-3-19Northland Securitiesn/aBuy
2019-3-19Mizuhon/aBuy
2019-3-12Mizuhon/aBuy

Zogenix stock analysis

Daily outlook

Shares of Zogenix closed today at $41.43 and stayed stable a tight 0.17%.

Zogenix stayed steady a tight 0.17% and closed at $41.43. Since Aug 27th when ZGNX stock price broke down the SMA200d line, it slid $-4.36 per share (-9.52%).

ZGNX stock chart (daily)

Weekly outlook

Zogenix shares declined -0.48% this week, ending at $41.43. Late August ZGNX collapsed a dreadful -17.15% in just one week.

Since price and 40-weeks moving average lines crossed down late August, ZGNX fell $-8.58 per share (-17.16%). Trading stocks that are under the 40-weeks (that is, 200-days) moving average line is not recommended by many experts, as it indicates that the stock has not enough institutional support.

ZGNX stock chart (weekly)

Zogenix stock price history

Zogenix stock went public on November 23rd, 2010 with a price of $40.001. Since then, ZGNX stock surged a 3.60%, with an average of 0.50% per year. If you had invested right after ZGNX's IPO a $1,000 in Zogenix stock in 2010, it would worth $36.00 today.

1: Adjusted price after possible price splits or reverse-splits.

Zogenix stock historical price chart

ZGNX stock reached 52-week highs on March at $56.50, and all-time highs 2018-07-13 with a price of 62.75.

Zogenix stock price target is $62.60

Nobody can reliably foresee how stock prices may evolve in the future. However, many stock price predictions are published every day by banks, financial institutions and independent analysts. You should not follow the analysts' ZGNX stock price predictions in the hope that they will be met as they may be wrong and not met. For the last 30 days we found 12 price predictions for Zogenix stock:
ZGNX stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-7-8Northland SecuritiesReiteratesn/a$60.00-
2019-6-28MizuhoReiterates$58.00$65.0012.1%
2019-6-28MizuhoRaises Target$58.00$65.0012.1%
2019-4-9Svb LeerinkLowers Target$60.00$48.00-20%
2019-4-9Stifel NicolausLowers Target$72.00$61.00-15.3%
2019-4-9Piper Jaffray CompaniesLowers Target$72.00$68.00-5.6%
2019-4-9MizuhoLowers Target$71.00$58.00-18.3%
2019-4-9Leerink SwannReiterates$60.00$48.00-20%
2019-4-5Northland SecuritiesSet Price Targetn/a$70.00-
2019-3-19Northland SecuritiesSet Price Targetn/a$70.00-
2019-3-19MizuhoReiteratesn/a$69.00-
2019-3-12MizuhoReiteratesn/a$69.00-
(in average)$64.40$62.60-3.0%
Moving in a range from $70.00 and $48.00, the price forecast for Zogenix stock is $62.60. In average, analysts' outlook on ZGNX price forecast is negative, downsizing the forecast by a -3.00% from previous estimations.

Financials and fundamental analysis

Earnings date and Earnings per Share

Zogenix disappointed experts on February when it reported an Earnings per Share (EPS) of $-0.53 when the analysts' forecast was $-1.00.
ZGNX earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise
2017-Q1-n/a-0.83n/a
2017-Q2-n/a-0.9n/a
2017-Q32017-11-06-0.97n/an/a
2017-Q42018-03-06-1.01-1.14n/a
2018-Q12018-05-09-0.74-0.87n/a
2018-Q22018-08-06-0.9-0.82n/a
2018-Q32018-11-08-0.88-0.93n/a
2018-Q42019-02-28-1-0.53n/a
2019-Q1-n/an/an/a
2019-Q2-n/an/an/a

Annual financial results

In 2017, Zogenix annual sales plummed a bloodcurdling -65.96% to $9.82 M USD from $28.85 marked in 2016. When comparing 2017 vs 2016, likewise, profit margin (that is, the net income divided by revenues) plunged a -1,049.67% to -1,291.28%.

ZGNX annual Sales and Income evolution
YearSalesYoYIncome/(margin)YoY
2013$33 M-$-80.86 M-245.0%-
2014$41 M22.78%$8.59 M21.2%-110.62%
2015$27 M-32.94%$26 M96.2%204.46%
2016$29 M6.14%$-69.71 M-241.6%-366.63%
2017$9.82 M-65.96%$-126.82 M-1291.3%81.93%

Quarterly financial results

Reported quarter earnings marked $-22.43 million with a profit margin of . Profit margin stayed steady a 0.00% compared to previous quarter when profit margin was inf%. When comparing sales to same quarter last year, Zogenix sales marked a neutral move and stayed constant a nan%. Looking back to recent quarterly results, Zogenix posted 6 positive quarters in a row.
ZGNX quarterly Sales and Income evolution
QuarterSales1QoQ2Income1/(margin)QoQ2
2017-Q1$2.70 M-$-21.13 M-782.6%-
2017-Q2$7.13 M164.07%$-22.45 M-314.9%6.25%

Zogenix ownership

When you are planning to invest in shares of a stock, it's worth to have a look its ownership structure.

Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Zogenix, 2.92% of all outstanding shares are owned by its staff.

Bearish positions for ZGNX stock account 0.00%, no big difference from last month.

The following table compares ownership indicators for other stocks related to Zogenix:

ZGNXALKSATRSCAHDRRX
Market cap$1.8 B$3.3 B$590.3 M$14.3 B$364.7 M
Total shares42.5 M157.1 M163.1 M298.1 M191.9 M
Float shares31.5 M155.3 M150.5 M296.9 M166.6 M
  - Institutional holdings (%)116.2%99.2%42.3%92.4%46.1%
  - Insider holdings (%)2.9%0.9%7.3%0.3%4.0%
Shares in short selling0.0%0.0%0.0%0.0%0.0%

Zogenix summary

Friday, September 20th, 2019
Open$41.22
Close$41.43
Day range$40.88 - $41.58
Previous close$41.36
Session gain0.17%
Average true range$1.51
50d mov avg$46.33
100d mov avg$43.47
200d mov avg$44.24
Daily patternlt03a
Weekly pattern

Zogenix performance

Performance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. For Zogenix, the benchmark is made against Alkermes, Antares Pharma, Cardinal Health, DURECT, , Eli Lilly and, Mallinckrodt, Merck, Nektar and Pfizer.
Stock3m6m12m
ZGNXZogenix1.99%-21.33%-15.71%
ALKSAlkermes-6.15%-37.57%-48.99%
ATRSAntares Pharma25.26%16.03%11.04%
CAHCardinal Health8.23%0.46%-9.30%
DRRXDURECT211.48%171.43%77.57%
JNJ-7.74%-3.60%-6.42%
LLYEli Lilly and-0.44%-9.87%9.89%
MNKMallinckrodt-72.80%-88.95%-91.77%
MRKMerck1.38%4.89%23.08%
NKTRNektar-42.20%-37.36%-65.85%
PFEPfizer-15.62%-11.17%-14.22%

Zogenix competitors

We selected a few stocks to conform a list of Zogenix competitors to review if you are interested in investing in ZGNX: